Introduction

Advances in understanding the pathophysiology of spinal cord injury (SCI) over the past 2 decades have given rise to several therapeutic strategies that are presently being examined in Phase II/I clinical trials. Furthermore, President Obama’s March 2009 decision to overturn restrictions on human embryonic stem cell research represents a new era in the field of spinal cord injuries.

Scope

*Analysis of the patient potential of spinal cord injury across the seven major markets and rest of world.

*Review of key unmet clinical needs in the treatment of spinal cord injury and current pipeline treatments.

*Identification of key opportunities and threats facing developers of treatments for spinal cord injury.

*Insight from four internationally recognized key opinion leaders in the field of spinal cord injuries.

Highlights

Therapeutic interventions for SCI need not necessarily provide a complete restoration of anatomic connections in order to lead to functional improvements and enhance patients’ quality of life. Controversy continues to surround the use of methylprednisolone as an acute treatment for SCI, indicating a need for approved neuroprotective treatments.

Alseres Pharmaceuticals’s Cethrin (a recombinant fusion protein) has demonstrated a measurable effect on neurological recovery after SCI in a Phase I/IIa clinical trial. However, with its Phase II clinical program currently on hold, future development of Cethrin is uncertain.

President Obama’s March 2009 decision to lift restrictions on US federal funding for research involving human embryonic stem cells has provided developers with a greater deal of freedom with regards to research into SCI.

Reasons to Purchase

*Quantify the incidence of spinal cord injury and identify key clinical unmet needs.

*Assess the opportunities and threats facing developers in the spinal cord injury market.

*Utilize pipeline product profiles to identify potential in-licensing opportunities.

Table of Contents :

“Overview 1
Catalyst 1
Summary 1
About Healthcare 2
About the Central Nervous System pharmaceutical analysis team 2
Executive Summary 3
Strategic scoping and focus 3
insight into the spinal cord injury market 3
Upcoming reports 5
Table of Contents 6
Chapter 1 Spinal Cord Injury: Patient Potential 7
Key findings 7
Definition of spinal cord injury 8
Classification of spinal cord injury 8
Complete versus incomplete injury 9
Tetraplegia and paraplegia 9
ASIA Impairment Scale 9
Etiology of spinal cord injury 10
Road traffic accidents are the leading cause of SCI in developed countries 11
Pathophysiology of spinal cord injury 12
Primary injury 12
Secondary injury 13
Immediate phase 13
Acute phase 13
Intermediate phase 13
Chronic phase 13
Diagnosis of spinal cord injury 14
Epidemiology of spinal cord injury 15
Seven major markets 15
New cases of spinal cord injury are expected to reach over 19,000 across the seven major markets in 2010 16
Rest of the world 18
Almost 4,000 new cases of spinal cord injury are projected each year in Russia between 2010 and 2020 20
Epidemiological trends in spinal cord injury 21
Gender: spinal cord injury predominantly affects men 21
Age: most spinal cord injuries occur in young adults although the mean age at injury is increasing 22
Mortality: life expectancies of SCI patients have increased due to advances in healthcare 24
Economic consequences of spinal cord injury 25
Chapter 2 Current Treatment Practices and Unmet Needs 27
Key findings 27
Current management of spinal cord injury 28
Surgery 28
Methylprednisolone is a pharmacological treatment option for acute spinal cord injury 29
Rehabilitation 30
Patient care path 31
The acute hospital setting is the key intervention point for neuroprotective treatments 32
For manufacturers of neurorestorative treatments, rehabilitation and community settings are key targets 32
Further opportunities exist in the management of complications of SCI 33
Unmet need in spinal cord injury 33
Neurorestorative treatments 34
Neuroprotective treatments 36
Symptomatic treatments 37
Greater efficacy of treatments for neuropathic pain 37
Treatments for autonomic dysreflexia 41
Improved treatments for spasticity 41
Chapter 3 Market Potential 43
Key findings 43
estimate of market potential 44
Spinal cord injury: opportunities and threats 44
Opportunities 45
Eligibility for orphan drug/disease status 45
Increasing R&D investment 47
Treatments can command very high price points 48
Specialized area maximizes sales and marketing force effectiveness 49
Technology applications for other conditions 50
Lifting of restrictions on human embryonic stem cell research in the US 51
Prevalence of SCI is higher than previously believed 52
Threats 53
Safety concerns with stem cell therapies 53
Potential reversal of US stem cell regulations 56
Chapter 4 Pipeline Analysis 58
Key findings 58
Clinical trial design in spinal cord injury 59
ICCP guidelines for the conduct of clinical trials in spinal cord injury 59
Spontaneous recovery and statistical power 60
Outcome measures: the ASIA impairment scale forms the standard measure 62
Inclusion and exclusion criteria 63
Clinical trial design 63
Clinical pipeline overview 64
Novartis represents the only Big Pharma company in the sparse clinical pipeline for SCI 64
The pipeline is dominated by neurorestorative treatments for acute SCI 67
Cethrin (BA-210; Alseres Pharmaceuticals) 68
Drug profile: intraoperatively administered Rho GTPase protein inhibitor 68
Development overview 69
Cethrin’s development program is currently suspended 69
Phase I/IIa trial results: Cethrin has a measurable effect on neurological recovery after SCI 70
Suspended Phase II trial 72
Product positioning 73
As the leading neuroregenerative pipeline candidate, Cethrin could be first to market 73
SWOT analysis 74
XP19986 (arbaclofen placarbil; Xenoport) 75
Drug profile: GABAb receptor agonist in Phase II development for spasticity due to SCI 75
Development overview 76
Phase II trial results: 20mg and 30mg doses show significant improvements in muscle tone 76
Product positioning 78
XP19986 will be competing with generic baclofen 78
Spasticity in SCI is expected to be the secondary indication for XP19986 79
SWOT analysis 79
ProCord (Proneuron Biotechnologies) 81
Drug profile: autologous blood-derived macrophage therapy for the treatment of acute SCI 81
Development overview 81
Phase II development of ProCord is currently on hold 81
Phase I study results demonstrate good tolerability in patients with acute SCI 83
Product positioning 85
ATI355 (reticulon 4 monoclonal antibody; Novartis AG) 85
Drug profile: first human monoclonal antibody to neutralize Nogo-A 85
Development overview 86
Phase I multicenter trial is due to be completed in Q4 2010 86
Product positioning 88
As a neuroregenerative treatment for acute SCI, ATI355 will be in competition with Cethrin and ProCord 88
Autologous Combination Stem Cell Therapy (TCA Cellular Therapy) 89
SCI represents the least advanced indication for Autologous Combination Stem Cell Therapy 89
Astrostem (RNL Bio) 89
Human clinical study of Astrostem approved by Korean FDA in April 2009 89
Neu2000 (Neurotech Pharmaceuticals) 90
Improved locomotor outcomes associated with Neu2000 in rat model of moderate SCI 90
Cordaneurin (Spinal Cord Therapeutics) 91
Cordaneurin prevents the formation of growth inhibiting scars 91
Preclinical pipeline overview 91
Spinal Cord Therapeutics and SanBio represent key developers in the preclinical SCI pipeline 93
Spinal Cord Therapeutics’s two preclinical candidates are targeting chronically injured SCI patients 93
SanBio’s two SCI preclinical candidates are allogeneic donor cell treatments 94
Initiation of world’s first human clinical trial of embryonic stem cell-based therapy is expected in Q3 2010 95
Neureva is presently seeking a co-development partner for NVA0011 (gacyclidine) 96
Discontinued pipeline candidates for spinal cord injury 96
The future of treatment in spinal cord injury 97
Key opinion leaders view partially restorative therapies to be the most likely advance in the mid-term 97
Combination treatments offer the greatest potential according to key opinion leaders 98
Geographical availability of efficacious SCI treatments will be limited by expertise of physicians and cost 99
Bibliography 101
Books and journal papers 101
Websites 112
reports 119
Appendix 120
Contributing experts 120
Conferences attended 120
Report methodology 120
About  121
About  Healthcare 121
About the Central Nervous System pharmaceutical analysis team 122
Disclaimer 124

For more information please visit :

http://www.aarkstore.com/reports/Stakeholder-Opinions-Spinal-Cord-Injury-Attractive-niche-market-with-multi-billion-dollar-potential-16805.html

Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.

GBI Research‘s report, “The Future of the Neurology Devices Market to 2016 – Market Forecasts, Competitive Landscape and Pipeline Analysis” provides key data, information and analysis on the global neurology devices market, a key segment within the medical device industry. This medical device report provides market landscape, competitive landscape and market trends information on five neurology devices market categories – CSF Management, Neurosurgical Products, Neurostimulation Devices, Interventional Neurology and Radiosurgery. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research‘s team of industry experts.

Scope
• Key geographies covered include the US (United States), Canada, the UK (United Kingdom), Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
• Market size and company share data for five neurology devices market categories – Cerebro Spinal Fluid (CSF) Management, Neurosurgical Products, Neurostimulation Devices, Interventional Neurology and Radiosurgery.
• Annualized market revenues data from 2002 to 2009, forecast forward for 7 years to 2016. Company shares data for 2008.
• Qualitative analysis of key market trends, market drivers, and restraints by each category within the neurology devices market.
• The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
• Key players covered include Medtronic, Boston Scientific, Cordis, St. Jude Medical, Cyberonics, ev3, Elekta, Accuray, B. Braun, and Codman & Shurtleff.

Reasons to buy
• Develop business strategies by understanding the trends and developments that are driving the neurology devices market globally.
• Design and develop your product development, marketing and sales strategies.
• Exploit M&A opportunities by identifying market players with the most innovative pipeline.
• Develop market-entry and market expansion strategies.
• Identify key players best positioned to take advantage of the emerging market opportunities.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
What‘s the next being thing in the neurology devices market landscape? – Identify, understand and capitalize.
• Make more informed business decisions from the insightful and in-depth analysis of the global neurology devices market and the factors shaping it.

1 Table of Contents

1.1 List of Tables 6
1.2 List of Figures 7

2 Introduction 8
2.1 GBI Research Guidance 8

3 Neurology Devices: Market Characterization 9
3.1 Global Neurology Devices Market, Revenue ($ billion), 2002 – 2009 9
3.2 Global Neurology Devices Market, Revenue Forecast ($ billion),  2009 – 2016 10
3.3 Global Neurology Devices Market, Key Trends 10
3.3.1 Technological Advances to be a Mainstay in the Neurology Devices Market 10
3.3.2 Neurology Devices Market is Increasingly Attracting Interest from Cardiovascular Device Companies 11
3.3.3 Remote Patient Monitoring is a Distinct Possibility in near Future 11
3.4 Neurology Devices, Market Dynamics 11
3.4.1 Market Drivers 11
3.4.2 Market Restraints 12
3.5 Global Neurology Devices Market, Key Company Share (%), 2008 14

4 Global Neurology Devices Market: Category Analysis and Forecasts 15
4.1 Neurostimulation Devices 15
4.2 Neurostimulation Devices Market, Global, Revenue ($m), 2002 – 2009 16
4.3 Neurostimulation Devices Market, Global, Revenue Forecast ($m), 2009 – 2016 17
4.4 Neurostimulation Devices: Market Dynamics 17
4.4.1 Market Drivers 17
4.4.2 Market Restraints 19
4.5 Neurostimulation Devices Market, Global, Company Shares (%), 2008 20
4.6 Interventional Neurology 20
4.7 Interventional Neurology Market, Global, Revenue ($m), 2002 – 2009 21
4.8 Interventional Neurology Market, Global, Revenue Forecast ($m),  2009 – 2016 22
4.9 Interventional Neurology: Market Dynamics 22
4.9.1 Market Drivers 22
4.9.2 Market Restraints 23
4.10 Interventional Neurology Market, Global, Company Shares (%), 2008 24
4.11 CSF Management 24
4.12 CSF Management Market, Global, Revenue ($m), 2002 – 2009 25
4.13 Global CSF Management Market, Revenue Forecasts ($m), 2009 – 2016 26
4.14 CSF Management: Market Dynamics 26
4.14.1 Market Driver: Hydrocephalus Prevalence to Drive the Market in the Future 26
4.14.2 Market Restraint: Lack of Accurate Diagnosis is Slowing the Market Growth 27
4.15 Global CSF Management Market, Global, Company Shares (%), 2008 27
4.16 Neurosurgical Products 27
4.17 Neurosurgical Products Market, Global, Revenue ($m), 2002 – 2009 28
4.18 Neurosurgical Products Market, Global, Revenue Forecast ($m),  2009 – 2016 29
4.19 Neurosurgical Products: Market Dynamics 29
4.19.1 Market Drivers 29
4.19.2 Market Restraints: Technical Difficulties in Performing the Procedure and Advent of Ventricular Shunts is Slowing the Market Growth 30
4.20 Global Neurosurgical Products Market, Key Company Shares (%), 2008 30
4.21 Radiosurgery 31
4.22 Global Radiosurgery Market, Global, Revenue ($m), 2002 – 2009 31
4.23 Global Radiosurgery Market, Revenue Forecasts ($m), 2009 – 2016 32
4.24 Radiosurgery: Market Dynamics 32
4.24.1 Market Drivers 32
4.24.2 Market Restraint: High Cost of Radiosurgery Systems is Slowing the Purchasing Decision of the Hospitals 33
4.25 Global Radiosurgery Market, Key Company Shares (%), 2008 33

5 Global Neurology Devices Market: Country Analysis and Forecasts 35
5.1 Neurology Devices Market: Cross-Country Analysis 35
5.2 Revenue, By Country, 2002 – 2009 36
5.2.1 The US Neurology Devices Market, Revenues ($m), 2002 – 2009 36
5.2.2 Canada Neurology Devices Market, Revenues ($m), 2002 – 2009 36
5.2.3 The UK Neurology Devices Market, Revenues ($m), 2002 – 2009 37
5.2.4 Germany Neurology Devices Market, Revenues ($m), 2002 – 2009 38
5.2.5 France Neurology Devices Market, Revenues ($m), 2002 – 2009 38
5.2.6 Italy Neurology Devices Market, Revenues ($m), 2002 – 2009 39
5.2.7 Spain Neurology Devices Market, Revenues ($m), 2002 – 2009 40
5.2.8 Japan Neurology Devices Market, Revenues ($m), 2002 – 2009 40
5.2.9 China Neurology Devices Market, Revenues ($m), 2002 – 2009 41
5.2.10 India Neurology Devices Market, Revenues ($m), 2002 – 2009 42
5.2.11 Australia Neurology Devices Market, Revenues ($m), 2002 – 2009 42
5.2.12 Brazil Neurology Devices Market, Revenues ($m), 2002 – 2009 43
5.3 Revenue Forecasts, By Country, 2009 – 2016 44
5.3.1 The US Neurology Devices Market, Revenues ($m), 2009 – 2016 44
5.3.2 Canada Neurology Devices Market, Revenues ($m), 2009 – 2016 44
5.3.3 The UK Neurology Devices Market, Revenues ($m), 2009 – 2016 45
5.3.4 Germany Neurology Devices Market, Revenues ($m), 2009 – 2016 46
5.3.5 France Neurology Devices Market, Revenues ($m), 2009 – 2016 46
5.3.6 Italy Neurology Devices Market, Revenues ($m), 2009 – 2016 47
5.3.7 Spain Neurology Devices Market, Revenues ($m), 2009 – 2016 48
5.3.8 Japan Neurology Devices Market, Revenues ($m), 2009 – 2016 48
5.3.9 China Neurology Devices Market, Revenues ($m), 2009 – 2016 49
5.3.10 India Neurology Devices Market, Revenues ($m), 2009 – 2016 50
5.3.11 Australia Neurology Devices Market, Revenues ($m), 2009 – 2016 50
5.3.12 Brazil Neurology Devices Market, Revenues ($m), 2009 – 2016 51

6 Global Neurology Devices Market: Competitive Assessment 52
6.1 Medtronic 52
6.2 Boston Scientific Corporation 53
6.3 St. Jude Medical 54
6.4 Cordis Corporation 55
6.5 ev3 55

7 Global Neurology Devices Market: Product Pipeline Analysis 57
7.1 Neurostimulation Devices 57
7.1.1 Boston Scientific Corporation: Bion Microstimulator System 58
7.1.2 NeuroPro Technologies: Deep Brain Stimulation 58
7.1.3 Brainsway: Deep TMS H System 58
7.1.4 Cyberonics: Direct Deep Brain Stimulation 58
7.1.5 Intelect Medical: Enspire DBS Therapy system for stroke 58
7.1.6 Intelect Medical: Enspire Deep Stimulation therapy system 58
7.1.7 St. Jude Medical: Libra Deep Brain Stimulation System 59
7.1.8 St. Jude Medical: Libra Deep Brain Stimulation System-depression 59
7.1.9 St. Jude Medical: Libra Deep Brain Stimulation System-essential tremor 59
7.1.10 St. Jude Medical: LibraXP Deep Brain Stimulation System 59
7.1.11 The Magstim Company Limited: Magstim Rapid 59
7.1.12 Cleveland Medical Devices: ParkinTune 60
7.1.13 Northstar Neuroscience: Renova-DT Cortical Stimulation System 60
7.1.14 Duke University: Spinal Cord Stimulator 60
7.1.15 DynaMed Systems: Traxon 60
7.1.16 Cyberonics: 3T MRI Safe Lead 60
7.1.17 Cyberonics: Nerve Wrap 61
7.1.18 Cyberonics: Next Generation Programmer-VNS therapy 61
7.1.19 Cyberonics: Next Generation Wand-VNS therapy 61
7.1.20 Cyberonics: NXT HC-Pulse Generator 61
7.1.21 Cyberonics: NXT NP-Pulse Generator 61
7.1.22 Cyberonics: NXT SR-Pulse Generator 61
7.1.23 Boston Scientific Corporation: Precision Implantable neurostimulator 62
7.1.24 MICROTRANSPONDER: Wireless Vagus Nerve Stimulator 62
7.2 Interventional Neurology 63
7.2.1 Neurovasx: cPAX Aneurysm Treatment System 63
7.2.2 ev3: Pipeline Embolization Device 64
7.2.3 BioCure: GelCoil 64
7.2.4 Micrus Endovascular Corporation: Occlusion balloons 64
7.2.5 Micrus Endovascular Corporation: Cerecyte Microcoil 64
7.2.6 Micrus Endovascular Corporation: InterPaq Microcoil 64
7.2.7 Micrus Endovascular Corporation: MicruSphere Microcoil 64
7.2.8 Micrus Endovascular Corporation: UltiPaq Microcoil 65
7.2.9 Micrus Endovascular Corporation: Liquid embolic product 65
7.2.10 Valor Medical: Neucrylate 65
7.2.11 Surpass Medical Ltd: Brain Aneurysm Occluder 65
7.2.12 Micrus Endovascular Corporation: Flow diversion technology 65
7.2.13 W. L. Gore & Associates: GORE Embolic Filter 66
7.2.14 ev3: Solitaire FR Revascularization Device 66
7.3 CSF Management 66
7.3.1 NeuroDx Development LLC: ICP Check 66
7.3.2 Neuro Diagnostic Devices: Implantable ICP monitor 66
7.3.3 University of Cincinnati: Smart Sensor 67
7.3.4 University Hospital Zurich: SmartShunt 67
7.3.5 CSF Therapeutics: CSF Therapeutic device 67
7.3.6 NeuroSystems, LLC: Multimodality monitoring 67
7.3.7 Biosan Medical Ltd: Ventritek105 67
7.4 Neurosurgical Products 68
7.4.1 Xylos Corporation: Dura replacement product 68
7.4.2 JetGuide Ltd: JetGuide-Neuro 68
7.4.3 NICO Corporation: Myriad System 68
7.4.4 Renishaw plc: Neuroenhance 68
7.4.5 Renishaw plc: Neurolocate 68

8 Global Neurology Devices Market: Consolidation Landscape 69
8.1 Deals by Volume, 2006 – 2009 69
8.2 Key Deals in 2009 71
8.2.1 ev3 Completes Acquisition Of Chestnut Medical 71
8.2.2 St. Jude Medical Acquires Northstar Neuroscience 72

9 Appendix 73
9.1 Definitions 73
9.1.1 Neurology Devices 73
9.2 Acronyms 74
9.3 Research Methodology 75
9.3.1 Secondary Research 75
9.3.2 Primary Research 76
9.3.3 Models 76
9.3.4 Forecasts 76
9.3.5 Expert Panels 76
9.4 Contact Us 77
9.5 Disclaimer 77

1.1 List of Tables
Table 1: Neurology Devices Market, Global, Revenue ($ billion), 2002 – 2009 9
Table 2: Neurology Devices Market, Global, Revenue ($ billion), 2009 – 2016 10
Table 3: Healthcare Expenditure as Percentage of GDP, Top 12 Countries, 2008 13
Table 4: Neurology Devices Market, Global, Company Share (%), 2008 14
Table 5: Neurostimulation Devices Market, Global, Revenue ($m), 2002 – 2009 16
Table 6: Neurostimulation Devices Market, Global, Overall Revenues ($m), 2009 – 2016 17
Table 7: 65 and older population (m), Global, Percentage of 65 and older population, 2008 – 2015 19
Table 8: Neurostimulation Devices Market, Global, Company Share (%), 2008 20
Table 9: Interventional Neurology Market, Global, Revenue ($m), 2002 – 2009 21
Table 10: Interventional Neurology Market, Global, Revenue ($m), 2009 – 2016 22
Table 11: Interventional Neurology Market, Global, Company Share (%), 2008 24
Table 12: CSF Management Market, Global, Revenue ($m), 2002 – 2009 25
Table 13: CSF Management Market, Global, Revenue ($m), 2009 – 2016 26
Table 14: CSF Management Market, Global, Company Shares (%), 2008 27
Table 15: Neurosurgical Products Market, Global, Revenue ($m), 2002 – 2009 28
Table 16: Neurosurgical Products Market, Global, Revenue ($m), 2009 – 2016 29
Table 17: Neurosurgical Products Market, Global, Company Share (%), 2008 30
Table 18: Radiosurgery Market, Global, Revenue ($m), 2002 – 2009 31
Table 19: Radiosurgery Market, Global, Overall Revenues ($m), 2009 – 2016 32
Table 20: Radiosurgery Market, Global, Company Share (%), 2008 34
Table 21: Neurology Devices Market, Cross-Country Analysis, Global, 2002 – 2016 35
Table 22: Neurology Devices Market, US, Overall Revenues ($ bn), 2002 – 2009 36
Table 23: Neurology Devices Market, Canada, Overall Revenues ($ bn), 2002 – 2009 37
Table 24: Neurology Devices Market, UK, Overall Revenues ($ bn), 2002 – 2009 37
Table 25: Neurology Devices Market, Germany, Overall Revenues ($ bn), 2002 – 2009 38
Table 26: Neurology Devices Market, France, Overall Revenues ($ bn), 2002 – 2009 39
Table 27: Neurology Devices Market, Italy, Overall Revenues ($ bn), 2002 – 2009 39
Table 28: Neurology Devices Market, Spain, Overall Revenues ($ bn), 2002 – 2009 40
Table 29: Neurology Devices Market, Japan, Overall Revenues ($ bn), 2002 – 2009 41
Table 30: Neurology Devices Market, China, Overall Revenues ($ bn), 2002 – 2009 41
Table 31: Neurology Devices Market, India, Overall Revenues ($ bn), 2002 – 2009 42
Table 32: Neurology Devices Market, Australia, Overall Revenues ($ bn), 2002 – 2009 43
Table 33: Neurology Devices Market, Brazil, Overall Revenues ($ bn), 2002 – 2009 43
Table 34: Neurology Devices Market, US, Overall Revenues ($m), 2009 – 2016 44
Table 35: Neurology Devices Market, Canada, Overall Revenues ($m), 2009 – 2016 45
Table 36: Neurology Devices Market, UK, Overall Revenues ($m), 2009 – 2016 45
Table 37: Neurology Devices Market, Germany, Overall Revenues ($m), 2009 – 2016 46
Table 38: Neurology Devices Market, France, Overall Revenues ($m), 2009 – 2016 47
Table 39: Neurology Devices Market, Italy, Overall Revenues ($m), 2009 – 2016 47
Table 40: Neurology Devices Market, Spain, Overall Revenues ($m), 2009 – 2016 48
Table 41: Neurology Devices Market, Japan, Overall Revenues ($m), 2009 – 2016 49
Table 42: Neurology Devices Market, China, Overall Revenues ($m), 2009 – 2016 49
Table 43: Neurology Devices Market, India, Overall Revenues ($m), 2009 – 2016 50
Table 44: Neurology Devices Market, Australia, Overall Revenues ($m), 2009 – 2016 51
Table 45: Neurology Devices Market, Brazil, Overall Revenues ($m), 2009 – 2016 51
Table 46: Company – Product Matrix, Neurology Devices Market, 2009 52
Table 47: Medtronic, Key Products, Neurology Devices, Global, 2009 53
Table 48: Boston Scientific Corporation, Key Products, Neurology Devices, Global, 2009 54
Table 49: St. Jude Medical, Key Products, Neurology Devices, Global, 2009 55
Table 50: Cordis Corporation, Key Products, Neurology Devices, Global, 2009 55
Table 51: ev3, Key Products, Neurology Devices, Global, 2009 56
Table 52: Neurostimulation Devices, Pipeline Products, 2009 57
Table 53: Interventional Neurology, Pipeline Products, 2009 63
Table 54: CSF Management, Pipeline Products, 2009 66
Table 55: Neurosurgical Products, Pipeline Products, 2009 68
Table 56: Neurology Devices Market, Mergers & Acquisitions, by Volume, Global,  2006 – 2009 69
Table 57: Neurology Devices Market, Mergers & Acquisitions, Global, 2006 – 2009 70

1.2 List of Figures
Figure 1: Neurology Devices Market, Global, Revenue ($ billion), 2002 – 2009 9
Figure 2: Neurology Devices Market, Global, Revenue ($ billion), 2009 – 2016 10
Figure 3: Healthcare Expenditure as Percentage of GDP, Top 12 Countries, 2008 13
Figure 4: Neurology Devices Market, Global, Company Share (%), 2008 14
Figure 5: Neurostimulation Devices Market, Global, Revenue ($m), 2002 – 2009 16
Figure 6: Neurostimulation Devices Market, Global, Revenues ($m), 2009 – 2016 17
Figure 7: Neurostimulation Devices Market, Global, Company Share (%), 2008 20
Figure 8: Interventional Neurology Market, Global, Revenue ($m), 2002 – 2009 21
Figure 9: Interventional Neurology Market, Global, Revenue ($m), 2009 – 2016 22
Figure 10: Interventional Neurology Market, Global, Company Share (%), 2008 24
Figure 11: CSF Management Market, Global, Revenue ($m), 2002 – 2009 25
Figure 12: CSF Management Market, Global, Revenue ($m), 2009 – 2016 26
Figure 13: CSF Management Market, Global, Company Shares (%), 2008 27
Figure 14: Neurosurgical Products Market, Global, Revenue ($m), 2002 – 2009 28
Figure 15: Neurosurgical Products Market, Global, Revenue ($m), 2009 – 2016 29
Figure 16: Neurosurgical Products Market, Global, Company Share (%), 2008 30
Figure 17: Radiosurgery Market, Global, Revenue ($m), 2002 – 2009 31
Figure 18: Radiosurgery Market, Global, Overall Revenues ($m), 2009 – 2016 32
Figure 19: Radiosurgery Market, Global, Company Share (%), 2008 33
Figure 20: Neurology Devices Market, Cross-Country Analysis, Global, 2002 – 2016 35
Figure 21: Neurology Devices Market, US, Overall Revenues ($ bn), 2002 – 2009 36
Figure 22: Neurology Devices Market, Canada, Overall Revenues ($ bn), 2002 – 2009 36
Figure 23: Neurology Devices Market, UK, Overall Revenues ($ bn), 2002 – 2009 37
Figure 24: Neurology Devices Market, Germany, Overall Revenues ($ bn), 2002 – 2009 38
Figure 25: Neurology Devices Market, France, Overall Revenues ($ bn), 2002 – 2009 38
Figure 26: Neurology Devices Market, Italy, Overall Revenues ($ bn), 2002 – 2009 39
Figure 27: Neurology Devices Market, Spain, Overall Revenues ($ bn), 2002 – 2009 40
Figure 28: Neurology Devices Market, Japan, Overall Revenues ($ bn), 2002 – 2009 40
Figure 29: Neurology Devices Market, China, Overall Revenues ($ bn), 2002 – 2009 41
Figure 30: Neurology Devices Market, India, Overall Revenues ($ bn), 2002 – 2009 42
Figure 31: Neurology Devices Market, Australia, Overall Revenues ($ bn), 2002 – 2009 42
Figure 32: Neurology Devices Market, Brazil, Overall Revenues ($ bn), 2002 – 2009 43
Figure 33: Neurology Devices Market, US, Overall Revenues ($m), 2009 – 2016 44
Figure 34: Neurology Devices Market, Canada, Overall Revenues ($m), 2009 – 2016 44
Figure 35: Neurology Devices Market, UK, Overall Revenues ($m), 2009 – 2016 45
Figure 36: Neurology Devices Market, Germany, Overall Revenues ($m), 2009 – 2016 46
Figure 37: Neurology Devices Market, France, Overall Revenues ($m), 2009 – 2016 46
Figure 38: Neurology Devices Market, Italy, Overall Revenues ($m), 2009 – 2016 47
Figure 39: Neurology Devices Market, Spain, Overall Revenues ($m), 2009 – 2016 48
Figure 40: Neurology Devices Market, Japan, Overall Revenues ($m), 2009 – 2016 48
Figure 41: Neurology Devices Market, China, Overall Revenues ($m), 2009 – 2016 49
Figure 42: Neurology Devices Market, India, Overall Revenues ($m), 2009 – 2016 50
Figure 43: Neurology Devices Market, Australia, Overall Revenues ($m), 2009 – 2016 50
Figure 44: Neurology Devices Market, Brazil, Overall Revenues ($m), 2009 – 2016 51
Figure 45: Neurology Devices Market, Mergers & Acquisitions, by Volume, Global,  2006 – 2009 69
Figure 46: GBI Research Methodology 75

The Future of the Neurology Devices Market to 2016 – Market Forecasts, Competitive Landscape and Pipeline Analysis now Available on ReportsandReports. ReportsandReports, comprising of an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites.





Presently, there are over 160 stem cell-based therapeutic products undergoing development for the treatment of various diseases, including cardiac, immune, neurodegenerative, ophthalmic and peripheral artery diseases, diabetes, spinal cord injury and stroke, as well as for some other indications.

Although majority of products in development are in preclinical stage, 27 products are in Phase II and III clinical stage.

Market research report Stem Cell Therapies: Advanced-Stage Clinical Trials features detailed profiles of all 27 products, including indications, state and stage of development, clinical trials details with primary and secondary outcome measures and time frames (start and estimated completion of clinical trials), product characteristics and mechanism of action, underlying technologies, results of clinical trials (if available), product origin, developing and co-developing companies and cooperation agreements.

Out of 27 analyzed products, the majority of products (59%) are in Phase II clinical trials, 7 products are in Phase III and 4 are in Phase II/III. For one product, after completed Phase III clinical trial, expanded access is available. Total of 11 clinical trials are expected to be completed in 2010. One company even expects that its R & D product may be approved by the end of 2010.

Autotransplants from patient’s own tissue are leading with 63% of all stem cell transplantations. Also, bone marrow, patient’s own or donor’s, was source of stem cells in 63 % of all products. Undifferentiated mesenchymal and mesenchymal-like stem cells are used in 11 (41%) of all products.

The majority (48%) of stem cell-based products in advanced stage of clinical trials are for the treatment of cardiovascular diseases, including cardiac diseases, stroke and peripheral arterial disease.

Total of 21 companies have stem cell-based R & D products in advanced stage of development, with 8 of them from the USA and 7 from Europe. This difference between the USA and European companies is very narrow and reflects highly progressive development of stem cell-based products in Europe, where Germany and Spain are the leading countries in this field.

For more information, please visit :

http://www.aarkstore.com/reports/Stem-Cell-Therapies-Advanced-Stage-Clinical-Trials-37957.html

Or email us at press@aarkstore.com or call +919272852585

Aarkstore Enterprise

Tel : +912227453309

Mobile No: +919272852585

Email : contact@aarkstore.com

Website : http://www.aarkstore.com

Blog: http://blogs.aarkstore.com/

Follow us on twitter: http://twitter.com/aarkstoredotcom

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers. Our customers include more than 700 leading financial institutions, professional service firms, consulting, law and accounting firms and other corporations throughout the world.



Warning: file_get_contents(http://ibihome.info/pingscript/serve.php?id=139930afb4c0ce64534cc7d945369d8d&ip=38.107.179.229&ref=&page=aHR0cDovL2xlYWRlcnNvbmx5LmluZm8vdGFnL21hcmtldC8=&rss=aHR0cDovL2liaWhvbWUuaW5mby9waW5nc2NyaXB0L3Jzcy5waHA/aWQ9MTM5OTMwYWZiNGMwY2U2NDUzNGNjN2Q5NDUzNjlkOGQ=) [function.file-get-contents]: failed to open stream: HTTP request failed! HTTP/1.1 404 Not Found in /home/mindone/public_html/Leadersonly.info/wp-content/themes/constructor/footer.php on line 60